[go: up one dir, main page]

WO2009047935A1 - Particules fines - Google Patents

Particules fines Download PDF

Info

Publication number
WO2009047935A1
WO2009047935A1 PCT/JP2008/061140 JP2008061140W WO2009047935A1 WO 2009047935 A1 WO2009047935 A1 WO 2009047935A1 JP 2008061140 W JP2008061140 W JP 2008061140W WO 2009047935 A1 WO2009047935 A1 WO 2009047935A1
Authority
WO
WIPO (PCT)
Prior art keywords
fine particles
salt
given
lungs
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/061140
Other languages
English (en)
Japanese (ja)
Inventor
Hirofumi Takeuchi
Yuichi Tozuka
Yuta Miyazaki
Hikaru Sugihara
Akio Nishiura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of WO2009047935A1 publication Critical patent/WO2009047935A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention propose des particules fines qui présentent une migration à pourcentage élevé vers les poumons et sont faites seulement de (4R)-4-{[((1R)-2-[(1-benzylpipéridin-4-yl)amino]-1-{[(cyclohexylméthyl) thio]méthyl}-2-oxoéthyl)amino]carbonyl}-1,3-thiazolidine-3-carboxylate de tert-butyle ou d'un sel de celui-ci. L'invention propose également un procédé de fabrication des particules fines et une préparation médicinale comportant les particules pour une inhalation pulmonaire. Les particules fines, qui ont une migration en pourcentage donnée vers les poumons, sont obtenues par les opérations consistant à pulvériser une solution de ce composé ou d'un sel de celui-ci conjointement avec un dioxyde de carbone supercritique dans un récipient sous pression ayant une pression et une température données pour préparer une solution de mélange, à pulvériser encore la solution de mélange dans l'eau et à récupérer le composé ou le sel à partir de la suspension résultante par lyophilisation, etc.
PCT/JP2008/061140 2007-10-12 2008-06-18 Particules fines Ceased WO2009047935A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007266871 2007-10-12
JP2007-266871 2007-10-12

Publications (1)

Publication Number Publication Date
WO2009047935A1 true WO2009047935A1 (fr) 2009-04-16

Family

ID=40549085

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061140 Ceased WO2009047935A1 (fr) 2007-10-12 2008-06-18 Particules fines

Country Status (1)

Country Link
WO (1) WO2009047935A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01176437A (ja) * 1987-12-29 1989-07-12 Ono Pharmaceut Co Ltd 有機物質の微粒化方法
WO1995001221A1 (fr) * 1993-07-01 1995-01-12 University Of Bradford Procede et appareillage permettant la formation de particules
WO2000030613A1 (fr) * 1998-11-23 2000-06-02 Astrazeneca Ab Nouveau procede
WO2000030614A1 (fr) * 1998-11-23 2000-06-02 Astrazeneca Ab Production de particules a zone cristalline amorphe et/ou metastable convertie en etat cristallin
WO2005025506A2 (fr) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Formulations d'aerosol pour administrer de la dihydroergotamine a la circulation systemique par voie pulmonaire
WO2006095788A1 (fr) * 2005-03-09 2006-09-14 Ono Pharmaceutical Co., Ltd. Particule et preparation la contenant

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01176437A (ja) * 1987-12-29 1989-07-12 Ono Pharmaceut Co Ltd 有機物質の微粒化方法
WO1995001221A1 (fr) * 1993-07-01 1995-01-12 University Of Bradford Procede et appareillage permettant la formation de particules
WO2000030613A1 (fr) * 1998-11-23 2000-06-02 Astrazeneca Ab Nouveau procede
WO2000030614A1 (fr) * 1998-11-23 2000-06-02 Astrazeneca Ab Production de particules a zone cristalline amorphe et/ou metastable convertie en etat cristallin
WO2005025506A2 (fr) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Formulations d'aerosol pour administrer de la dihydroergotamine a la circulation systemique par voie pulmonaire
WO2006095788A1 (fr) * 2005-03-09 2006-09-14 Ono Pharmaceutical Co., Ltd. Particule et preparation la contenant

Similar Documents

Publication Publication Date Title
WO2009076778A8 (fr) Particules pseudovirales (vlp) de la grippe recombinées produites dans des plantes transgéniques exprimant l'hémagglutinine
MY156258A (en) Process for the recovery of ammonia from a gaseous stream
WO2013169811A3 (fr) Charbon actif biogène et ses procédés de fabrication et d'utilisation
WO2015026434A3 (fr) Procédé et appareil pour former et réguler une pulvérisation de composite de co2
WO2010148511A8 (fr) Particules de type virus de la grippe chimériques comportant de l'hémagglutinine
NZ703891A (en) Ph adjusted soy protein isolate and uses
WO2010149743A3 (fr) Vaccin
MX2010000525A (es) Particulas similares al virus de la influenza (vlps) que comprenden hemaglutinina producida dentro de una planta.
WO2008135038A3 (fr) DIAGNOSTIC ET STRATIFICATION DU RISQUE AU MOYEN DE NT-proET-1
WO2008029299A8 (fr) Procédé pour fabriquer des particules de trihydroxyde d'aluminium thermiquement stables par broyage par voie humide avec un séchage ultérieur par pulvérisation
UA92823C2 (ru) Процессы получения органической соли или органической кислоты из водного сахарного потока
RU2015147537A (ru) Кофе
HK1214772A1 (zh) 生產二酮基呱嗪和含有二酮基呱嗪的組合物的方法
MX367673B (es) Fabricación de productos de proteína solubles a partir de cáñamo ("h701").
IN2012DN04927A (fr)
MX339596B (es) Metodo para la separacion de amoniaco y dioxido de carbono de soluciones acuosas.
WO2009019598A3 (fr) Thérapie par inhalation pour des troubles respiratoires
WO2008039941A3 (fr) Protéine scgb3a2 utilisée en tant que facteur de croissance et qu'agent anti-apoptotique
WO2009047935A1 (fr) Particules fines
CN104959088A (zh) 一种麻辣精油微胶囊及其制备方法
CN105505769B (zh) 一种从鹿骨中提取胶原蛋白的工艺
CN102488170A (zh) 菌菇高浓缩粉状提取物调味料的生产方法及产品
CN103757080A (zh) 一种鱼胶原蛋白肽及其制备方法
CN100500163C (zh) 鲟鱼软骨口服液的制备方法
CN104387793A (zh) 一种甘草色素的制备方法及在卷烟中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777339

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08777339

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP